Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 140,418	$ 49,826
Marketable securities	259,715	193,482
Interest receivable	375	240
Accounts receivable	4,673	3,343
Prepaid expenses and other current assets	5,340	1,506
Total current assets	410,521	248,397
Marketable securities, non-current		1,012
Property and equipment, net	78,723	31,066
Intangible assets	54,866
Goodwill	40,044	1,585
Other non-current assets	2,741	1,181
Non-current restricted cash	3,500	3,500
Total assets	590,395	286,741
Current liabilities:
Accounts payable and accrued liabilities	21,457	11,035
Accrued compensation and employee benefits	9,490	5,479
Deferred revenues	47,564	28,345
Total current liabilities	78,511	44,859
Deferred revenues, non-current	108,273	29,244
Build-to-suit lease obligation	27,689	24,738
Deferred income tax	6,705
Non-current liabilities	1,960
Total liabilities	223,138	98,841
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value; 160,000,000 shares authorized, 102,187,471 and 85,598,534 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	1,022	856
Additional paid-in capital	929,632	682,809
Accumulated deficit	(562,696)	(495,479)
Accumulated other comprehensive loss	(1,440)	(286)
Total Sangamo Therapeutics Inc. stockholders' equity	366,518	187,900
Non-controlling interest	739
Total stockholders' equity	367,257	187,900
Total liabilities and stockholders' equity	$ 590,395	$ 286,741